Clinical Study

Uccc-Hn-20-01- Phase 1B/II Trial Combining Pd1 Inhibition (Pembrolizumab) And Cesium 131 Brachytherapy With Salvage Surgery To Enhance Immunogenicity And Improve Local Control In Head And Neck Cancer

Posted Date: May 5, 2021

  • Investigator: Shuchi Gulati
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Device & Drug

The main purpose of this study is to determine the safety and disease free survival of Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.

Criteria:

Locally Recurrent Hnscc And Be Eligible For Salvage Surgery, If Patient Received Radiation Therapy In The Past, They Should Have Recovered From The Acute Toxicity To

Keywords:

Head And Cancer

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.